Lipella Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment. In March 2023, Lipella created a five-member Scientific Advisory Board in Oral Health, made up of a group of highly regarded experts in oral medicine, to focus on the development of LP-310. This team helped craft the clinical strategy and will be involved in the recruitment of high-quality clinical sites.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 USD | +2.31% | +6.56% | -23.53% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.53% | 5.8M | |
+9.06% | 114B | |
+11.46% | 104B | |
-12.80% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.32% | 17.89B | |
+8.17% | 14.28B | |
+34.98% | 12.55B |
- Stock Market
- Equities
- LIPO Stock
- News Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus